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and Charles E. Canter, MD,a St Louis, MoS
evere pulmonary hypertension unresponsive to acute pul-
monary vasodilators—‘‘fixed’’ or ‘‘irreversible’’ pulmo-
nary hypertension—has traditionally been regarded as
a contraindication to an orthotopic heart transplant. We re-
port a novel strategy of combining mechanical biventricular assist
device (BiVAD) support provided by the Berlin Heart EXCOR de-
vice (Berlin Heart AG, Berlin, Germany) with medical pulmonary
vasodilator therapy in the cases of 2 children initially referred to
our institution for a heart–lung transplant because of heart failure
and presumed irreversible pulmonary hypertension. In both cases,
our approach significantly improved the pulmonary hypertension,
permitting an orthotopic heart transplant alone, a procedure with
a much better long-term prognosis than a heart–lung transplant.
Case Reports
PATIENT 1. Patient 1 was a 2-year-old boy with congenitally
corrected transposition of the great arteries, congenital heart block,
and a small ventricular septal defect. He had undergone implantation
of a single-chamber epicardial pacemaker as a neonate. He was seen
at 2 years with worsening ventricular failure. Cardiac catheterization
at that time demonstrated a pulmonary vascular resistance (PVR) of
15 Woods units/m2 and a transpulmonary gradient of 40 mm Hg, un-
responsive to oxygen or inhaled nitric oxide (Table 1).
Initiation of intravenous epoprostenol therapy and placement of
a dual-chamber biventricular pacemaker in an attempt to optimize
ventricular function and reduce PVR were poorly tolerated and re-
sulted in significant cardiac instability. Ultimately, the child was
placed on extracorporeal membrane oxygenation support. After 8
days of extracorporeal membrane oxygenation, the patient was tran-
sitioned to mechanical BiVAD support with the EXCOR system.
The patient was weaned from extracorporeal circulation without dif-
ficulty and extubated at 1 week. He was maintained on a regimen of
intravenous epoprostenol (initiated at 1 ng/[kg $ min] and increased
to 20 ng/[kg $ min] over 3 weeks), oral sildenafil citrate (INN silde-
nafil, 5 mg four times daily), and oxygen by nasal cannula (2 L/min,
inspired oxygen fraction 100%). During the next 4 weeks, the pa-
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at 1 month after BiVAD implantation demonstrated normal pulmo-
nary arterial pressures and normal PVR (Table 1). The patient under-
went a successful orthotopic heart transplant 1 week later. His
pulmonary arterial pressures in the operating room were normal.
The child was extubated on postoperative day 2 and discharged
from the hospital on postoperative day 12. Epoprostenol was tapered
over 2 weeks, and sildenafil citrate was tapered over 3 months. The
patient has undergone numerous postoperative endomyocardial bi-
opsies with nearly normal hemodynamics. He remains clinically
well 18 months after his heart transplant.
PATIENT 2. The second patient was a 10-month-old girl with
a presentation of failure to thrive who was discovered to have a re-
strictive cardiomyopathy and severe pulmonary hypertension. Ana-
tomically, she had a very small left ventricle, probably representing
a forme fruste of hypoplastic left heart syndrome. Cardiac catheter-
ization demonstrated a PVR of 11 Wood units/m2 and a transpulmo-
nary gradient of 42 mm Hg, minimally responsive to a combination
of oxygen and inhaled nitric oxide (Table 2). The patient was started
on a regimen of intravenous epoprostenol (initiated at 1 ng/[kg $
min] and titrated to 15 ng/[kg $ min] over 2 weeks), milrinone (1
mg/[kg $ min]), and oral sildenafil citrate (3 mg four times daily)
and was also maintained on inhaled nitric oxide (20 ppm by nasal
cannula). Repeat cardiac catheterization 2 weeks after the initiation
of medical therapy demonstrated only minimal improvement in the
pulmonary hypertension. The decision was made to implant EX-
COR BiVADs. In addition to maintenance of inhaled nitric oxide
therapy, the epoprostenol was aggressively upwardly titrated (to
a maximum dose of 40 ng/[kg $ min]) and the sildenafil dosing
was increased (7 mg by mouth four times daily). At 6 postoperative
weeks, the PVR had dropped to 4.6 Woods units/m2 and the trans-
pulmonary gradient had declined to 14 mm Hg. At 10 postoperative
weeks, a successful orthotopic heart transplant was performed. The
patient’s immediate postoperative course was uneventful. Epopros-
tenol was tapered over 3 weeks, and she was discharged on postop-
erative day 25. Sildenafil citrate was tapered over 2 months. The
patient’s posttransplant hemodynamics normalized, and she remains
clinically well 6 months after her heart transplant.
Discussion
Severe pulmonary hypertension, especially associated with congen-
ital heart disease, has traditionally been regarded as an absolute con-
traindication to a cardiac transplant alone because of the prohibitive
risk of right ventricular failure in the allograft.1 The outlook for
these patients has changed, however, with the advent of potent
pulmonary vasodilators. Patients with heart failure and pulmonary
hypertension responsive to such agents acutely in the cardiac cath-
eterization laboratory are considered to have reversible lung disease
and are thus possible candidates for a heart transplant alone. Those
patients whose pulmonary pressures do not respond are considered
to have ‘‘fixed’’ or ‘‘irreversible’’ lung disease and are notracic and Cardiovascular Surgery c Volume 136, Number 2 529
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After heart transplant
Baseline iNO and 100% FIO2 After BiVADs (4 wk) 1 wk 1 y
Systemic pressure (mm Hg) 75/47 74/47 120/80 106/66 100/45
Pulmonary arterial pressure (mm Hg) 74/36 72/47 29/10 19/11 21/11
Transpulmonary gradient (mm Hg) 40 38 4 10 9
Cardiac index (L/[min $ m2]) 2.9 2.3 2.9 3.4 3.7
Pulmonary vascular resistance (Woods units/m2) 15 17.7 1.4 1.8 1.3
iNO, Inhaled nitric oxide; FIO2, inspired oxygen fraction; BiVADs; biventricular assist devices.considered eligible for a heart transplant alone. The traditional tenets
of PVR with regard to a heart transplant are brought into question by
the 2 cases in this report. Acute irreversibility in the catheterization
laboratory may not equate to irreversibility over the course of weeks
to months with pulmonary vasodilator therapy, mechanical ventric-
ular assistance, or both. In these 2 cases, we reversed what was ini-
tially designated as irreversible pulmonary hypertension by using
a combined surgical and medical approach. This strategy ultimately
allowed a successful isolated orthotopic heart transplant. Our results
suggest that the classification of who is eligible for a heart transplant
should be broadened.
Although the pathophysiology of pulmonary hypertension in pa-
tients with heart failure is complex and multifactorial, it is in large
part related to elevated left atrial filling pressures, which are a conse-
quence of impaired left (systemic) ventricular systolic and diastolic
function and, in many cases, systemic atrioventricular valve pathol-
ogy. Left atrial hypertension translates into increased postcapillary
pressure in the pulmonary circulation, which unleashes a cascade
of biochemical responses, resulting in endothelial dysfunction, inti-
mal thickening, and smooth muscle cell proliferation and throm-
bosis.2 Whereas in idiopathic pulmonary hypertension these
derangements are seemingly progressive and unalterable, our
patients and other data suggest that in patients whose lung disease
is secondary to heart failure, this process can be halted or even
reversed.
Continuous unloading of the left ventricle, thereby lowering left
atrial pressure, is the theoretic basis for ventricular assist device
implantation in these patients as a mechanism of improving their
pulmonary hypertension. There is information in adults that this
unloading of the left ventricle, accomplished by left ventricular as-
sist device insertion, reduces elevated PVR over time.3 Most of
these previously described adult patients have had a modest (5–6Woods units/m2) elevation of PVR, unlike the extreme pulmonary
hypertension present in the children in this report. In addition,
most have not had severe right heart failure and have thus undergone
isolated left ventricular assist device implantation. As recent techno-
logic advancements have made ventricular assist devices applicable
even to infants, even the smallest child with end-stage heart failure
and lung disease may benefit from their use.
We combined the use of mechanical ventricular assistance with
aggressive use of pulmonary vasodilators. Animal and human stud-
ies have implicated several molecular mechanisms in the develop-
ment of pulmonary hypertensive changes.4 Such medications as
inhaled nitric oxide, phosphodiesterase 5 inhibitors, endothelin re-
ceptor antagonists, and epoprostenol analogs have been shown not
only to reduce pulmonary arterial pressure acutely but also to re-
verse some of the pathologic remodeling that has already occurred
in the pulmonary vascular bed. The clinical application of combina-
tion medical pulmonary vasodilator therapy to affect chronic pulmo-
nary hypertension is becoming more widespread5 and may be
particularly effective in children, in whom the chronicity of vascular
changes is relatively short relative to adults. This pharmacotherapy
is also an important adjunct in the immediate posttransplant period,
when allograft function may be compromised by even mildly
elevated pulmonary arterial pressures.
Our results suggest that patients with end-stage heart disease and
severe pulmonary hypertension may be successful candidates for
a heart transplant alone, instead of a heart–lung transplant. When
evaluating children for a heart transplant in situations where fixed
pulmonary hypertension is apparently present, consideration should
be given to an aggressive trial of medical pulmonary vasodilators. If
these prove ineffective, implantation of BiVADs in concert with
medical therapy may resurrect the potential of a heart transplant
for a patient previously considered ineligible.TABLE 2. Patient 2's hemodynamic variables at baseline and after interventions
Baseline
iNO and
100% FIO2
After therapy*
(2 wk)
After BiVADs After heart transplant
3 wk 6 wk 6 wk 6 mo
Systemic pressure (mm Hg) 80/50 67/36 96/64 100/50 105/55 114/55 110/60
Pulmonary arterial pressure (mm Hg) 96/41 58/22 80/48 57/15 48/8 18/11 30/17
Transpulmonary gradient (mm Hg) 42 23 34 21 14 8 10
Cardiac index (L/[min $ m2]) 3.9 3.9 3.6 3.0 3.0 4.6 5.3
Pulmonary vascular resistance (Woods units/m2) 11 8 9.2 7 4.6 2.1 1.9
iNO, Inhaled nitric oxide; FIO2, inspired oxygen fraction; BiVADs; biventricular assist devices. *Therapy with epoprostenol, milrinone, sildenafil citrate [INN
sildenafil], and inhaled nitric oxide.
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in acute infective endocarditis
Igor E. Konstantinov, MD, PhD, Perth, Australia
A
cute infective endocarditis of the tricuspid valve (TV) in
noncompliant intravenous drug abusers presents a diffi-
cult problem. Progressive sepsis despite appropriate an-
tibiotics necessitates surgical intervention. These
noncompliant patients, however, often leave the hospital against
medical advice. The risk of prosthetic endocarditis in this group
of patients is very high. Complete resection of the valve without re-
placement, although feasible, can result in progressive right-sided
heart failure. Reconstruction of the TV might be an alternative op-
tion.
Clinical Summary
A 33-year-old man with a long history of intravenous drug abuse was
admitted with fever and chills. He previously underwent drainage of
an infected left hip joint, as well as multiple bilateral groin abscesses
at the site of drug injection. Multiple blood cultures demonstrated
Staphylococcus aureus. Despite appropriate antibiotic coverage, un-
controlled sepsis developed. Echocardiographic analysis demon-
strated large multiple vegetations of the TV (Figure 1, A) and an
abscess extending into the free wall of the right ventricle. This infec-
tive process involved all 3 leaflets, causing TV stenosis (Figure 1,C).
The patient underwent urgent surgical intervention. Total resec-
tion of the TV and the entire subvalvular apparatus was performed.
The right ventricular abscess was drained. The entire operation was
performed on the beating heart with cardiopulmonary bypass. The
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TV was reconstructed with autologous pericardium soaked in rifam-
picin (Figure 1, B-D and E) and polytetrafluoroethylene* cords. Apart
from 4-0 polytetrafluoroethylene cords and 4-0 Prolene sutures, no
artificial material was used. After complete resection of all infected
tissues, a distance from the papillary muscles or right ventricular
wall was measured by using a Silastic tube at approximately two
thirds of the distance to the TV annulus (Figure 2, A). A polytetra-
fluoroethylene suture was then placed through the free edge of the re-
constructed leaflet, right ventricular myocardium, and pericardial
pledget and introduced into the previously sized tube (Figure 2, B).
The polytetrafluoroethylene cord was then tightened with the tube
in place to prevent incidental shortening of the cord while tightening
the knots (Figure 2, C). The tube was then removed, and the recon-
structed leaflet was retracted (Figure 2, D and E). Each leaflet was
suspended by 3 cords placed in a similar fashion (Figure 2, F-H).
The pulmonary artery was then clamped. The newly reconstructed
valve was tested with warm normal saline with the heart beating to
recreate a normal anatomy of the distended right ventricle. Postoper-
ative echocardiographic analysis demonstrated normal function of
the reconstructed TV and subvalvular apparatus (Figure 1, B). The
patient is asymptomatic at 3 months of follow-up yet continues to
abuse drugs.
Discussion
Surgical treatment of acute right-sided endocarditis is associated
with significant mortality.1 Compete destruction of the TV in a non-
compliant patient is a difficult problem. These patients often leave
the hospital despite medical advice once they feel better and do
not complete the full course of antibiotics. Recurrences of endocar-
ditis are common. Replacement of the valve with a prosthesis carries
a very high risk of prosthetic endocarditis, whereas valve excision
results in massive tricuspid regurgitation. Although successful re-
pair of acute TV endocarditis involving a single leaflet has been re-
ported,2 a complete reconstruction after total resection of the TV is
a much more challenging procedure. A simplified technique for
* Gore-Tex cord, registered trademark of W. L. Gore & Associates, Inc, New-
ark, Del.
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